Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve

Circulation

Volumn 132, Issue 8, 2015, Pages 677-690

  Bouchareb, Rihab ^a   Mahmut, Ablajan ^a   Nsaibia, Mohamed Jalloul ^a   Boulanger, Marie Chloé ^a   Dahou, Abdellaziz ^b   Lépine, Jamie Lee ^a   Laflamme, Marie Hélène ^a   Hadji, Fayez ^a   Couture, Christian ^b   Trahan, Sylvain ^b   Pagé, Sylvain ^b   Bossé, Yohan ^b   Pibarot, Philippe ^b   Scipione, Corey A ^c   Romagnuolo, Rocco ^c   Koschinsky, Marlys L ^c   Arsenault, Benoît J ^b   Marette, André ^b   Mathieu, Patrick ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF WINDSOR   (Canada)

Author keywords

aortic stenosis calcific; aortic valve stenosis; autotaxin; calcific aortic valve disease; ENPP2; lipoprotein(a); lipoproteins; lysophosphatidic acid; lysophosphatidylcholine

Indexed keywords

APOLIPOPROTEIN A; AUTOTAXIN; BONE MORPHOGENETIC PROTEIN; HYDROXYAPATITE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPROTEIN A; LYSOPHOSPHATIDIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4H1; PHOSPHOLIPID; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; PHOSPHODIESTERASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA VALVE; AORTA VALVE DISEASE; ARTICLE; CALCIFIC AORTIC VALVE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEART MUSCLE CELL; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; MALE; MINERALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSTHORACIC ECHOCARDIOGRAPHY; VALVE INTERSTITIAL CELL; AGED; ANIMAL; AORTA VALVE STENOSIS; BIOSYNTHESIS; C57BL MOUSE; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; PATHOLOGY; SECRETION (PROCESS);

AGED; ANIMALS; AORTIC VALVE; AORTIC VALVE STENOSIS; FEMALE; HUMANS; INFLAMMATION; LIPOPROTEIN(A); MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; PHOSPHORIC DIESTER HYDROLASES;

EID: 84940655915     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.016757     Document Type: Article

References (28)

1. Messika-Zeitoun D, Aubry MC, Detaint D, Bielak LF, Peyser PA, Sheedy PF, Turner ST, Breen JF, Scott C, Tajik AJ, Enriquez-Sarano M., Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. Circulation 2004 110 356 362. doi: 10.1161/01.CIR.0000135469.82545.D0
2. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O'Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM., Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation 2011 124 1783 1791. doi: 10.1161/CIRCULATIONAHA.110.006767
3. Otto CM., Calcific aortic stenosis-Time to look more closely at the valve. N Engl J Med 2008 359 1395 1398. doi: 10.1056/NEJMe0807001
4. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, Malhotra R, O'Brien KD, Kamstrup PR, Nordestgaard BG, Tybjaerg-Hansen A, Allison MA, Aspelund T, Criqui MH, Heckbert SR, Hwang SJ, Liu Y, Sjogren M, van der Pals J, Kälsch H, Mühleisen TW, Nöthen MM, Cupples LA, Caslake M, Di Angelantonio E, Danesh J, Rotter JI, Sigurdsson S, Wong Q, Erbel R, Kathiresan S, Melander O, Gudnason V, O'Donnell CJ, Post WS, CHARGE Extracoronary Calcium Working Group Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013 368 503 512. doi: 10.1056/NEJMoa1109034
5. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG., Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014 63 470 477. doi: 10.1016/j.jacc.2013.09.038
6. Arsenault BJ, Boekholdt SM, Dube MP, Rheaume E, Wareham NJ, Khaw KT, Sandhu MS, Tardif JC., Lipoprotein(a) levels, genotype and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet 2014 34 457 462
7. O'Donoghue ML, Morrow DA, Tsimikas S, Sloan S, Ren AF, Hoffman EB, Desai NR, Solomon SD, Domanski M, Arai K, Chiuve SE, Cannon CP, Sacks FM, Sabatine MS., Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol 2014 63 520 527. doi: 10.1016/j.jacc.2013.09.042
8. Mahmut A, Boulanger MC, El Husseini D, Fournier D, Bouchareb R, Després JP, Pibarot P, Bossé Y, Mathieu P., Elevated expression of lipoprotein-Associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. J Am Coll Cardiol 2014 63 460 469. doi: 10.1016/j.jacc.2013.05.105
9. Leibundgut G, Scipione C, Yin H, Schneider M, Boffa MB, Green S, Yang X, Dennis E, Witztum JL, Koschinsky ML, Tsimikas S., Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res 2013 54 2815 2830. doi: 10.1194/jlr.M040733
10. Liu SY, Lu X, Choy S, Dembinski TC, Hatch GM, Mymin D, Shen X, Angel A, Choy PC, Man RY., Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation. Cardiovasc Res 1994 28 1476 1481
11. Wu R, Huang YH, Elinder LS, Frostegård J., Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol 1998 18 626 630
12. Lehti S, Käkelä R, Hörkkö S, Kummu O, Helske-Suihko S, Kupari M, Werkkala K, Kovanen PT, Oörni K., Modified lipoprotein-derived lipid particles accumulate in human stenotic aortic valves. PLoS One 2013 8 e65810. doi: 10.1371/journal.pone.0065810
13. Nakanaga K, Hama K, Aoki J., Autotaxin-An LPA producing enzyme with diverse functions. J Biochem 2010 148 13 24. doi: 10.1093/jb/mvq052
14. Sun W, Li H, Yu Y, Fan Y, Grabiner BC, Mao R, Ge N, Zhang H, Fu S, Lin X, Yang J., MEKK3 is required for lysophosphatidic acid-induced NF-kappaB activation. Cell Signal 2009 21 1488 1494. doi: 10.1016/j.cellsig.2009.05.007
15. Schober A, Siess W., Lysophosphatidic acid in atherosclerotic diseases. Br J Pharmacol 2012 167 465 482. doi: 10.1111/j.1476-5381.2012.02021.x
16. El Husseini D, Boulanger MC, Mahmut A, Bouchareb R, Laflamme MH, Fournier D, Pibarot P, Bossé Y, Mathieu P., P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease. J Mol Cell Cardiol 2014 72 146 156. doi: 10.1016/j.yjmcc.2014.02.014
17. Baker DL, Desiderio DM, Miller DD, Tolley B, Tigyi GJ., Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal Biochem 2001 292 287 295. doi: 10.1006/abio.2001.5063
18. Le Quang K, Bouchareb R, Lachance D, Laplante MA, El Husseini D, Boulanger MC, Fournier D, Fang XP, Avramoglu RK, Pibarot P, Deshaies Y, Sweeney G, Mathieu P, Marette A., Early development of calcific aortic valve disease and left ventricular hypertrophy in a mouse model of combined dyslipidemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2014 34 2283 2291. doi: 10.1161/ATVBAHA.114.304205
19. Côté C, Pibarot P, Després JP, Mohty D, Cartier A, Arsenault BJ, Couture C, Mathieu P., Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008 94 1175 1180. doi: 10.1136/hrt.2007.125740
20. Côté N, Pibarot P, Pépin A, Fournier D, Audet A, Arsenault B, Couture C, Poirier P, Després JP, Mathieu P., Oxidized low-density lipoprotein, angiotensin II and increased waist circumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. Int J Cardiol 2010 145 444 449. doi: 10.1016/j.ijcard.2009.05.054
21. Mohty D, Pibarot P, Després JP, Côté C, Arsenault B, Cartier A, Cosnay P, Couture C, Mathieu P., Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008 28 187 193. doi: 10.1161/ATVBAHA.107.154989
22. Taleb A, Witztum JL, Tsimikas S., Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med 2011 5 673 694. doi: 10.2217/bmm.11.60
23. Hung MY, Witztum JL, Tsimikas S., New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-Associated phospholipase A2-oxidized phospholipid axis. J Am Coll Cardiol 2014 63 478 480. doi: 10.1016/j.jacc.2013.08.1639
24. Mahmut A, Mahjoub H, Boulanger MC, Fournier D, Després JP, Pibarot P, Mathieu P., Lp-PLA2 is associated with structural valve degeneration of bioprostheses. Eur J Clin Invest 2014 44 136 145. doi: 10.1111/eci.12199
25. Wu JM, Xu Y, Skill NJ, Sheng H, Zhao Z, Yu M, Saxena R, Maluccio MA., Autotaxin expression and its connection with the TNF-Alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol Cancer 2010 9 71. doi: 10.1186/1476-4598-9-71
26. Perrakis A, Moolenaar WH., Autotaxin: structure-function and signaling. J Lipid Res 2014 55 1010 1018. doi: 10.1194/jlr.R046391
27. Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, Karshovska E, Megens R, Heyll K, Chun J, Saulnier-Blache JS, Reinholz M, van Zandvoort M, Weber C, Schober A., Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab 2011 13 592 600. doi: 10.1016/j.cmet.2011.02.016
28. Federico L, Pamuklar Z, Smyth SS, Morris AJ., Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Curr Drug Targets 2008 9 698 708